Kura Oncology to Report Third Quarter 2017 Financial Results
31 oct. 2017 16h05 HE
|
Kura Oncology, Inc.
SAN DIEGO, Oct. 31, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology Development Candidate KO-539 Shows Robust Preclinical Anti-Tumor Activity in NPM1- and DNMT3A-Mutant AML
28 oct. 2017 12h30 HE
|
Kura Oncology, Inc.
NPM1 and DNMT3A-mutants comprise approximately 45% of AML patientsMenin-MLL complex appears to be central node in epigenetic dysregulation giving rise to AML SAN DIEGO, Oct. 28, 2017 (GLOBE...
Kura Oncology Lead Candidate Tipifarnib Shows Durable Anti-Tumor Activity in HRAS Mutant Head and Neck Cancer in AACR-NCI-EORTC Update
27 oct. 2017 10h50 HE
|
Kura Oncology, Inc.
Confirmed partial responses observed in four out of six patients with HRAS mutant HNSCCTipifarnib demonstrates rapid and durable responses, with partial responses observed beyond one...
Kura Oncology Announces Late-Breaking Presentations for Tipifarnib in HRAS Mutant Squamous Head and Neck Cancer and for KO-539 in AML at Upcoming AACR-NCI-EORTC International Conference
16 oct. 2017 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, Oct. 16, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology Announces Positive Phase 2 Study for Tipifarnib in HRAS Mutant Head and Neck Cancer
07 sept. 2017 16h05 HE
|
Kura Oncology, Inc.
Four of the first six HRAS mutant HNSCC patients enrolled on study achieve confirmed RECIST partial responses Durable responses greater than one year observed SAN DIEGO, Sept. 07, 2017 (GLOBE...
Kura Oncology to Participate in Citi’s 12th Annual Biotech Conference
29 août 2017 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, Aug. 29, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology Announces Pricing of Public Offering of Common Stock
10 août 2017 22h11 HE
|
Kura Oncology, Inc.
SAN DIEGO, Aug. 10, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology Announces Commencement of Public Offering of Common Stock
09 août 2017 16h16 HE
|
Kura Oncology, Inc.
SAN DIEGO, Aug. 09, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology Reports Second Quarter 2017 Financial Results and Provides Update on Tipifarnib Phase 2 Study
07 août 2017 16h05 HE
|
Kura Oncology, Inc.
Tipifarnib demonstrates high level of clinical activity and durable partial responses in ongoing Phase 2 trial in HRAS mutant squamous cell head and neck cancers Management to host webcast and...
Kura Oncology to Report Second Quarter 2017 Financial Results
31 juil. 2017 07h30 HE
|
Kura Oncology, Inc.
LA JOLLA, Calif., July 31, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology,...